Zoetis (ZTS) Stock Forecast & Price Target

Zoetis has demonstrated significant growth in its customer engagement efforts, with the enrollment in Zoetis Petcare Rewards increasing markedly to 2.5 million pet owners from 708,000 in 2018, supported by over $120 million invested in 2023 for marketing initiatives. In the third quarter, the company's product Simparica contributed $356 million in revenue, reflecting a year-over-year growth of 7%, while key dermatological products, including Apoquel and Cytopoint, achieved a 3% increase in global revenue, totaling $469 million. These factors, combined with Zoetis's robust market share in both companion and production animal segments, underline a strong financial outlook for the company.

Zoetis has revised its 2025 revenue guidance downward to between $9.400 billion and $9.475 billion, reflecting organic operational growth expectations of 5.5% to 6.5%, which is a decrease from previous estimates of 6.5% to 8.0%. The company's orthopedic pain business has reported an 11% decline year-over-year, attributed to negative publicity surrounding the safety profile of its product Librela. Furthermore, the third quarter of 2025 showed a modest revenue increase of only 1%, falling short of both internal and consensus estimates, primarily due to stagnant performance in the core U.S. companion animal health segment and increased competition amidst reduced vet clinic visits.